Printer Friendly
The Free Library
23,375,127 articles and books


TRANSITION TO BEGIN ISLET NEOGENESIS U.K. PHASE I TRIAL.

Transition Therapeutics Inc. (TSX VENTURE:TTH) ("Transition"), Toronto, Canada, has received approval to begin a dose escalating Phase I human trial in the United Kingdom of its Islet Neogenesis Therapy (I.N.T.(TM)), a therapy that has been demonstrated in pre-clinical studies to be effective at stimulating the body to regenerate insulin producing cells and reducing diabetic symptoms.

"The approval of the Phase I represents a significant milestone for the company and demonstrates that Transition is focused on rapidly moving products to the clinic." said Tony Cruz, chairman and CEO of Transition Therapeutics Inc.

Transition expects the trial to be complete by early 2003.

Transition believes that I.N.T. represents a new paradigm in the treatment of diabetes because it consists of a simple, non-invasive regenerative therapy that mimics the normal development of insulin producing cells. I.N.T. is a short course of injections of two well-defined human growth factors that stimulates the body to regenerate insulin producing cells that are damaged or destroyed in those with insulin-dependent diabetes. This treatment has the potential of reducing, and in some case eliminating, the need for insulin injections.

The initiation of Phase I human trials for I.N.T. has enabled the company to commence closure of its laboratory facility in Woburn, Mass. and reduce its headcount that was dedicated to the pre-clinical development of I.N.T. Senior officers affected by the closure included Dr. Stephen Brand, Dr. Sheila Magil, and Phil Shapiro. Brand will remain associated with Transition in an advisory capacity.

About Transition Therapeutics

Transition Therapeutics Inc. is a publicly listed biopharmaceutical company developing innovative therapeutics focusing on the treatment of multiple sclerosis, diabetes and restenosis. Transition offers a deep product portfolio and a strong management team with expertise in product development. Transition's management intends to continue to build shareholder value by rapidly and cost effectively advancing products from discovery to the clinic and licensing to corporate partners.

For more information, call 416/260-7770 Ext. 224 or visit http://www.transitiontherapeutics.com.
COPYRIGHT 2002 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:1CANA
Date:Nov 1, 2002
Words:336
Previous Article:BIRTH CONTROL PATCH APPROVED BY HEALTH CANADA AND EC.
Next Article:BTG ANNOUNCES NOVEL INSULIN THERAPY FOR TREATMENT OF DIABETES.



Related Articles
Sweet success in freezing islets.
Mouse study suggests diabetes prevention.
Camouflaged grafts elude immune detection.
Transplanted Hopes.
TRANXENOGEN SIGNS MONOCLONAL ANTIBODY DEVELOPMENT PACTS.
Selected ongoing clinical trials. (Featured CME Topic: Diabetes Mellitus).
AMGEN, NEOGENESIS TEAM ON DRUG.
AMGEN SIGNS WITH SWEDISH DRUG COMPANY.
Cell transplants stop diabetes in some patients.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters